Targeting chromosomal instability in patients with cancer.
Journal
Nature reviews. Clinical oncology
ISSN: 1759-4782
Titre abrégé: Nat Rev Clin Oncol
Pays: England
ID NLM: 101500077
Informations de publication
Date de publication:
11 Jul 2024
11 Jul 2024
Historique:
accepted:
20
06
2024
medline:
12
7
2024
pubmed:
12
7
2024
entrez:
11
7
2024
Statut:
aheadofprint
Résumé
Chromosomal instability (CIN) is a hallmark of cancer and a driver of metastatic dissemination, therapeutic resistance, and immune evasion. CIN is present in 60-80% of human cancers and poses a formidable therapeutic challenge as evidenced by the lack of clinically approved drugs that directly target CIN. This limitation in part reflects a lack of well-defined druggable targets as well as a dearth of tractable biomarkers enabling direct assessment and quantification of CIN in patients with cancer. Over the past decade, however, our understanding of the cellular mechanisms and consequences of CIN has greatly expanded, revealing novel therapeutic strategies for the treatment of chromosomally unstable tumours as well as new methods of assessing the dynamic nature of chromosome segregation errors that define CIN. In this Review, we describe advances that have shaped our understanding of CIN from a translational perspective, highlighting both challenges and opportunities in the development of therapeutic interventions for patients with chromosomally unstable cancers.
Identifiants
pubmed: 38992122
doi: 10.1038/s41571-024-00923-w
pii: 10.1038/s41571-024-00923-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Nature Limited.
Références
Orr, B., Godek, K. M. & Compton, D. Aneuploidy. Curr. Biol. 25, R538–542 (2015).
pubmed: 26126276
pmcid: 4714037
doi: 10.1016/j.cub.2015.05.010
Lejeune, J. & Turpin, R. Chromosomal aberrations in man. Am. J. Hum. Genet. 13, 175–184 (1961).
pubmed: 13760631
pmcid: 1932067
Arber, D. A. et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140, 1200–1228 (2022).
pubmed: 35767897
pmcid: 9479031
doi: 10.1182/blood.2022015850
Torres, E. M. et al. Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science 317, 916–924 (2007).
pubmed: 17702937
doi: 10.1126/science.1142210
Torres, E. M., Springer, M. & Amon, A. No current evidence for widespread dosage compensation in S. cerevisiae. eLife 5, e10996 (2016).
pubmed: 26949255
pmcid: 4798953
doi: 10.7554/eLife.10996
Santaguida, S., Vasile, E., White, E. & Amon, A. Aneuploidy-induced cellular stresses limit autophagic degradation. Genes Dev. 29, 2010–2021 (2015).
pubmed: 26404941
pmcid: 4604343
doi: 10.1101/gad.269118.115
Lukow, D. A. et al. Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies. Dev. Cell 56, 2427–2439.e4 (2021).
pubmed: 34352222
pmcid: 8933054
doi: 10.1016/j.devcel.2021.07.009
Ippolito, M. R. et al. Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy. Dev. Cell 56, 2440–2454.e6 (2021).
pubmed: 34352223
doi: 10.1016/j.devcel.2021.07.006
Schvartzman, J. M., Duijf, P. H., Sotillo, R., Coker, C. & Benezra, R. Mad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibition. Cancer Cell 19, 701–714 (2011).
pubmed: 21665145
pmcid: 3120099
doi: 10.1016/j.ccr.2011.04.017
Nguyen, B. et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 185, 563–575.e11 (2022).
pubmed: 35120664
pmcid: 9147702
doi: 10.1016/j.cell.2022.01.003
Agustinus, A. S. et al. Epigenetic dysregulation from chromosomal transit in micronuclei. Nature 619, 176–183 (2023).
pubmed: 37286593
pmcid: 10322720
doi: 10.1038/s41586-023-06084-7
Papathanasiou, S. et al. Heritable transcriptional defects from aberrations of nuclear architecture. Nature 619, 184–192 (2023).
pubmed: 37286600
pmcid: 10322708
doi: 10.1038/s41586-023-06157-7
Beach, R. R. et al. Aneuploidy causes non-genetic individuality. Cell 169, 229–242.e21 (2017).
pubmed: 28388408
pmcid: 5441241
doi: 10.1016/j.cell.2017.03.021
Martínez-Ruiz, C. et al. Genomic–transcriptomic evolution in lung cancer and metastasis. Nature 616, 543–552 (2023).
pubmed: 37046093
pmcid: 10115639
doi: 10.1038/s41586-023-05706-4
Bakhoum, S. F. et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature 553, 467–472 (2018).
pubmed: 29342134
pmcid: 5785464
doi: 10.1038/nature25432
McPherson, A. et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat. Genet 48, 758–767 (2016).
pubmed: 27182968
doi: 10.1038/ng.3573
Roylance, R. et al. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol. Biomark. Prev. 20, 2183–2194 (2011).
doi: 10.1158/1055-9965.EPI-11-0343
Stopsack, K. H. et al. Aneuploidy drives lethal progression in prostate cancer. Proc. Natl Acad. Sci. USA 116, 11390–11395 (2019).
pubmed: 31085648
pmcid: 6561291
doi: 10.1073/pnas.1902645116
Chibon, F., Lesluyes, T., Valentin, T. & Le Guellec, S. CINSARC signature as a prognostic marker for clinical outcome in sarcomas and beyond. Genes Chromosomes Cancer 58, 124–129 (2019).
pubmed: 30387235
doi: 10.1002/gcc.22703
Frankell, A. M. et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature 616, 525–533 (2023).
pubmed: 37046096
pmcid: 10115649
doi: 10.1038/s41586-023-05783-5
Sourty, B., La Basset, Ë., Garcion, E. & Rousseau, A. DNAR-01. Chromothripsis, one major genetic instability factor in glioblastoma, is rare in IDH-mutant gliomas. Neuro-Oncology 24, vii90 (2022).
pmcid: 9660868
doi: 10.1093/neuonc/noac209.334
Luebeck, J. et al. Extrachromosomal DNA in the cancerous transformation of Barrett’s oesophagus. Nature 616, 798–805 (2023).
pubmed: 37046089
pmcid: 10132967
doi: 10.1038/s41586-023-05937-5
Bakhoum, S. F. & Compton, D. A. Kinetochores and disease: keeping microtubule dynamics in check! Curr. Opin. Cell Biol. 24, 64–70 (2012).
pubmed: 22196931
doi: 10.1016/j.ceb.2011.11.012
de Oliveira Lisboa, M., Brofman, P. R. S., Schmid-Braz, A. T., Rangel-Pozzo, A. & Mai, S. Chromosomal instability in acute myeloid leukemia. Cancers 13, 2655 (2021).
pubmed: 34071283
pmcid: 8198625
doi: 10.3390/cancers13112655
Lee, A. J. et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 71, 1858–1870 (2011).
pubmed: 21363922
pmcid: 3059493
doi: 10.1158/0008-5472.CAN-10-3604
van Dijk, E. et al. Chromosomal copy number heterogeneity predicts survival rates across cancers. Nat. Commun. 12, 3188 (2021).
pubmed: 34045449
pmcid: 8160133
doi: 10.1038/s41467-021-23384-6
Al Bakir, M. et al. The evolution of non-small cell lung cancer metastases in TRACERx. Nature 616, 534–542 (2023).
pubmed: 37046095
pmcid: 10115651
doi: 10.1038/s41586-023-05729-x
Li, M. et al. The ATM–p53 pathway suppresses aneuploidy-induced tumorigenesis. Proc. Natl Acad. Sci. USA 107, 14188–14193 (2010).
pubmed: 20663956
pmcid: 2922543
doi: 10.1073/pnas.1005960107
Laughney, A. M., Elizalde, S., Genovese, G. & Bakhoum, S. F. Dynamics of tumor heterogeneity derived from clonal karyotypic evolution. Cell Rep. 12, 809–820 (2015).
pubmed: 26212324
doi: 10.1016/j.celrep.2015.06.065
Al-Rawi, D. H. & Bakhoum, S. F. Chromosomal instability as a source of genomic plasticity. Curr. Opin. Genet. Dev. 74, 101913 (2022).
pmcid: 9156567
doi: 10.1016/j.gde.2022.101913
Bakhoum, S. F. & Cantley, L. C. The multifaceted role of chromosomal instability in cancer and its microenvironment. Cell 174, 1347–1360 (2018).
pubmed: 30193109
pmcid: 6136429
doi: 10.1016/j.cell.2018.08.027
Thompson, S. L., Bakhoum, S. F. & Compton, D. A. Mechanisms of chromosomal instability. Curr. Biol. 20, R285–295 (2010).
pubmed: 20334839
pmcid: 3781365
doi: 10.1016/j.cub.2010.01.034
Bronder, D. & Bakhoum, S. F. A. CINful way to overcome addiction: how chromosomal instability enables cancer to overcome its oncogene addiction. EMBO Mol. Med. 12, e12017 (2020).
pubmed: 32072755
pmcid: 7059011
doi: 10.15252/emmm.202012017
Sotillo, R., Schvartzman, J. M., Socci, N. D. & Benezra, R. Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature 464, 436–440 (2010).
pubmed: 20173739
pmcid: 2841716
doi: 10.1038/nature08803
Harrold, E. et al. Molecular and clinical determinants of acquired resistance and treatment duration for targeted therapies in colorectal cancer. Clin. Cancer Res. 30, 2672–2683 (2024).
pubmed: 38502113
pmcid: 11176917
doi: 10.1158/1078-0432.CCR-23-4005
Liu, Y. L. et al. Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer. Gynecol. Oncol. 155, 51–57 (2019).
pubmed: 31421916
pmcid: 6788969
doi: 10.1016/j.ygyno.2019.08.006
Kaya, A. et al. Molecular signatures of aneuploidy-driven adaptive evolution. Nat. Commun. 11, 588 (2020).
pubmed: 32001709
pmcid: 6992709
doi: 10.1038/s41467-019-13669-2
Santaguida, S. & Amon, A. Short- and long-term effects of chromosome mis-segregation and aneuploidy. Nat. Rev. Mol. Cell Biol. 16, 473–485 (2015).
pubmed: 26204159
doi: 10.1038/nrm4025
Schukken, K. M. & Foijer, F. CIN and aneuploidy: different concepts, different consequences. BioEssays 40, https://doi.org/10.1002/bies.201700147 (2018).
Baker, D. J. et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat. Genet. 36, 744–749 (2004).
pubmed: 15208629
doi: 10.1038/ng1382
Macedo, J. C. et al. FoxM1 repression during human aging leads to mitotic decline and aneuploidy-driven full senescence. Nat. Commun. 9, 2834 (2018).
pubmed: 30026603
pmcid: 6053425
doi: 10.1038/s41467-018-05258-6
Andriani, G. A. et al. Whole chromosome instability induces senescence and promotes SASP. Sci. Rep. 6, 35218 (2016).
pubmed: 27731420
pmcid: 5059742
doi: 10.1038/srep35218
Santaguida, S. et al. Chromosome mis-segregation generates cell-cycle-arrested cells with complex karyotypes that are eliminated by the immune system. Dev. Cell 41, 638–651.e5 (2017).
pubmed: 28633018
pmcid: 5536848
doi: 10.1016/j.devcel.2017.05.022
Wang, R. W., Viganò, S., Ben-David, U., Amon, A. & Santaguida, S. Aneuploid senescent cells activate NF-κB to promote their immune clearance by NK cells. EMBO Rep. 22, e52032 (2021).
pubmed: 34105235
pmcid: 8339690
doi: 10.15252/embr.202052032
Hsu, S.-K. et al. Unfolded protein response (UPR) in survival, dormancy, immunosuppression, metastasis, and treatments of cancer cells. Int. J. Mol. Sci. 20, 2518 (2019).
pubmed: 31121863
pmcid: 6566956
doi: 10.3390/ijms20102518
Scharping, N. E. et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45, 374–388 (2016).
pubmed: 27496732
pmcid: 5207350
doi: 10.1016/j.immuni.2016.07.009
Reveil, P. O. Recherches de Physiologie Vegetale. De l’Action des Poisons sur les Plantes (E Martinet, 1865).
Gusev, Y., Kagansky, V. & Dooley, W. C. Long-term dynamics of chromosomal instability in cancer: a transition probability model. Math. Comput. Model. 33, 1253–1273 (2001).
doi: 10.1016/S0895-7177(00)00313-7
Brennan, C. M. et al. Protein aggregation mediates stoichiometry of protein complexes in aneuploid cells. Genes Dev. 33, 1031–1047 (2019).
pubmed: 31196865
pmcid: 6672052
doi: 10.1101/gad.327494.119
Oromendia, A. B., Dodgson, S. E. & Amon, A. Aneuploidy causes proteotoxic stress in yeast. Genes Dev. 26, 2696–2708 (2012).
pubmed: 23222101
pmcid: 3533075
doi: 10.1101/gad.207407.112
Pfau, S. J. & Amon, A. Chromosomal instability and aneuploidy in cancer: from yeast to man. EMBO Rep. 13, 515–527 (2012).
pubmed: 22614003
pmcid: 3367249
doi: 10.1038/embor.2012.65
Stingele, S. et al. Global analysis of genome, transcriptome and proteome reveals the response to aneuploidy in human cells. Mol. Syst. Biol. 8, 608 (2012).
pubmed: 22968442
pmcid: 3472693
doi: 10.1038/msb.2012.40
Ohashi, A. et al. Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells. Nat. Commun. 6, 7668 (2015).
pubmed: 26144554
doi: 10.1038/ncomms8668
Deshaies, R. J. Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol. 12, 94 (2014).
pubmed: 25385277
pmcid: 4226866
doi: 10.1186/s12915-014-0094-0
Donnelly, N., Passerini, V., Dürrbaum, M., Stingele, S. & Storchová, Z. HSF1 deficiency and impaired HSP90‐dependent protein folding are hallmarks of aneuploid human cells. EMBO J. 33, 2374–2387 (2014).
pubmed: 25205676
pmcid: 4253526
doi: 10.15252/embj.201488648
Morimoto, R. I. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev. 22, 1427–1438 (2008).
pubmed: 18519635
pmcid: 2732416
doi: 10.1101/gad.1657108
Li, J. et al. Non-cell-autonomous cancer progression from chromosomal instability. Nature 620, 1080–1088 (2023).
pubmed: 37612508
pmcid: 10468402
doi: 10.1038/s41586-023-06464-z
Li, J. et al. Metastasis and immune evasion from extracellular cGAMP hydrolysis. Cancer Discov. 11, 1212–1227 (2021).
pubmed: 33372007
doi: 10.1158/2159-8290.CD-20-0387
Advani, V. M. & Ivanov, P. Translational control under stress: reshaping the translatome. BioEssays 41, e1900009 (2019).
pubmed: 31026340
pmcid: 6541386
doi: 10.1002/bies.201900009
Pan, T. Adaptive translation as a mechanism of stress response and adaptation. Annu. Rev. Genet. 47, 121–137 (2013).
pubmed: 23988117
pmcid: 4109725
doi: 10.1146/annurev-genet-111212-133522
Lee, Y. S., Shibata, Y., Malhotra, A. & Dutta, A. A novel class of small RNAs: tRNA-derived RNA fragments (tRFs). Genes Dev. 23, 2639–2649 (2009).
pubmed: 19933153
pmcid: 2779758
doi: 10.1101/gad.1837609
Sun, C. et al. Roles of tRNA-derived fragments in human cancers. Cancer Lett. 414, 16–25 (2018).
pubmed: 29107107
doi: 10.1016/j.canlet.2017.10.031
Calvo, V. et al. Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors. Bioorg. Med. Chem. Lett. 43, 128058 (2021).
pubmed: 33895276
doi: 10.1016/j.bmcl.2021.128058
Stokes, M. E. et al. PERK inhibition by HC-5404 sensitizes renal cell carcinoma tumor models to antiangiogenic tyrosine kinase inhibitors. Clin. Cancer Res. 29, 4870–4882 (2023).
pubmed: 37733811
pmcid: 10690095
doi: 10.1158/1078-0432.CCR-23-1182
Ghosh, R. et al. Allosteric inhibition of the IRE1α RNase preserves cell viability and function during endoplasmic reticulum stress. Cell 158, 534–548 (2014).
pubmed: 25018104
pmcid: 4244221
doi: 10.1016/j.cell.2014.07.002
Tufanli, O. et al. Targeting IRE1 with small molecules counteracts progression of atherosclerosis. Proc. Natl Acad. Sci. USA 114, E1395–E1404 (2017).
pubmed: 28137856
pmcid: 5338400
doi: 10.1073/pnas.1621188114
Gabrail, N. Y. et al. A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 39, 3080 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.3080
Rimawi, M. F. et al. Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors. J. Clin. Oncol. 41, https://doi.org/10.1200/JCO.2023.41.16_suppl.1092 (2023).
Wilhelm, T. et al. Mild replication stress causes chromosome mis-segregation via premature centriole disengagement. Nat. Commun. 10, 3585 (2019).
pubmed: 31395887
pmcid: 6687892
doi: 10.1038/s41467-019-11584-0
Zeman, M. K. & Cimprich, K. A. Causes and consequences of replication stress. Nat. Cell Biol. 16, 2–9 (2014).
pubmed: 24366029
pmcid: 4354890
doi: 10.1038/ncb2897
Gemble, S. et al. Genetic instability from a single S phase after whole-genome duplication. Nature 604, 146–151 (2022).
pubmed: 35355016
pmcid: 8986533
doi: 10.1038/s41586-022-04578-4
Peng, C. et al. The error-prone DNA polymerase κ promotes temozolomide resistance in glioblastoma through Rad17-dependent activation of ATR-Chk1 signaling. Cancer Res. 76, 2340–2353 (2016).
pubmed: 26960975
doi: 10.1158/0008-5472.CAN-15-1884
Patterson, K. et al. Altered RECQL5 expression in urothelial bladder carcinoma increases cellular proliferation and makes RECQL5 helicase activity a novel target for chemotherapy. Oncotarget 7, 76140–76150 (2016).
pubmed: 27764811
pmcid: 5342802
doi: 10.18632/oncotarget.12683
Urban, V., Dobrovolna, J. & Janscak, P. Distinct functions of human RecQ helicases during DNA replication. Biophys. Chem. 225, 20–26 (2017).
pubmed: 27876204
doi: 10.1016/j.bpc.2016.11.005
Viziteu, E. et al. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma. Leukemia 31, 2104–2113 (2017).
pubmed: 28186131
pmcid: 5629372
doi: 10.1038/leu.2017.54
Santana-Codina, N. et al. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat. Commun. 9, 4945 (2018).
pubmed: 30470748
pmcid: 6251888
doi: 10.1038/s41467-018-07472-8
Li, Q. et al. Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer. Nat. Commun. 11, 1456 (2020).
pubmed: 32193458
pmcid: 7081201
doi: 10.1038/s41467-020-15308-7
Ge, X. Q., Jackson, D. A. & Blow, J. J. Dormant origins licensed by excess Mcm2–7 are required for human cells to survive replicative stress. Genes Dev. 21, 3331–3341 (2007).
pubmed: 18079179
pmcid: 2113033
doi: 10.1101/gad.457807
Lee, C. H. et al. Telaglenastat plus everolimus in advanced renal cell carcinoma: a randomized, double-blinded, placebo-controlled, phase II ENTRATA trial. Clin. Cancer Res. 28, 3248–3255 (2022).
pubmed: 35576438
pmcid: 10202043
doi: 10.1158/1078-0432.CCR-22-0061
Meric-Bernstam, F. et al. Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an open-label phase I trial. Clin. Cancer Res. 28, 1540–1548 (2022).
pubmed: 35140121
doi: 10.1158/1078-0432.CCR-21-2972
Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal. Cell 173, 581–594.e12 (2018).
pubmed: 29656895
pmcid: 5938365
doi: 10.1016/j.cell.2018.03.057
Addie, R. D. et al. Metabolic reprogramming related to whole-chromosome instability in models for Hürthle cell carcinoma. Sci. Rep. 10, 9578 (2020).
pubmed: 32533088
pmcid: 7293353
doi: 10.1038/s41598-020-66599-1
Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).
pubmed: 13298683
doi: 10.1126/science.123.3191.309
Warburg, O. On respiratory impairment in cancer cells. Science 124, 269–270 (1956).
pubmed: 13351639
doi: 10.1126/science.124.3215.269
Dai, C., Sun, F., Zhu, C. & Hu, X. Tumor environmental factors glucose deprivation and lactic acidosis induce mitotic chromosomal instability – an implication in aneuploid human tumors. PLoS ONE 8, e63054 (2013).
pubmed: 23675453
pmcid: 3651256
doi: 10.1371/journal.pone.0063054
Shaukat, Z. et al. Chromosomal instability causes sensitivity to metabolic stress. Oncogene 34, 4044–4055 (2015).
pubmed: 25347746
doi: 10.1038/onc.2014.344
Bahreyni, A. et al. Role of adenosine signaling in the pathogenesis of breast cancer. J. Cell Physiol. 233, 1836–1843 (2018).
pubmed: 28383816
doi: 10.1002/jcp.25944
Barfeld, S. J. et al. Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer. Oncotarget 6, 12587–12602 (2015).
pubmed: 25869206
pmcid: 4494960
doi: 10.18632/oncotarget.3494
Parker, W. B. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem. Rev. 109, 2880–2893 (2009).
pubmed: 19476376
pmcid: 2827868
doi: 10.1021/cr900028p
Newman, D. L. & Gregory, S. L. Operation between aneuploidy and metabolic changes in driving tumorigenesis. Int. J. Mol. Sci. 20, 4611 (2019).
pubmed: 31540349
pmcid: 6770258
doi: 10.3390/ijms20184611
Brault, V. et al. Opposite phenotypes of muscle strength and locomotor function in mouse models of partial trisomy and monosomy 21 for the proximal Hspa13-App region. PLoS Genet. 11, e1005062 (2015).
pubmed: 25803843
pmcid: 4372517
doi: 10.1371/journal.pgen.1005062
Clemente-Ruiz, M. et al. Gene dosage imbalance contributes to chromosomal instability-induced tumorigenesis. Dev. Cell 36, 290–302 (2016).
pubmed: 26859353
doi: 10.1016/j.devcel.2016.01.008
Prasad, S., Gupta, S. C. & Tyagi, A. K. Reactive oxygen species (ROS) and cancer: role of antioxidative nutraceuticals. Cancer Lett. 387, 95–105 (2017).
pubmed: 27037062
doi: 10.1016/j.canlet.2016.03.042
Ragu, S. et al. Oxygen metabolism and reactive oxygen species cause chromosomal rearrangements and cell death. Proc. Natl Acad. Sci. USA 104, 9747–9752 (2007).
pubmed: 17535927
pmcid: 1887571
doi: 10.1073/pnas.0703192104
Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96, 857–868 (1999).
pubmed: 10102273
doi: 10.1016/S0092-8674(00)80595-4
Limaye, V. et al. Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood 105, 3169–3177 (2005).
pubmed: 15632208
doi: 10.1182/blood-2004-02-0452
Zhou, J., Chen, Y., Lang, J.-Y., Lu, J.-J. & Ding, J. Salvicine inactivates β1 integrin and inhibits adhesion of MDA-MB-435 cells to fibronectin via reactive oxygen species signaling. Mol. Cancer Res. 6, 194–204 (2008).
pubmed: 18314480
doi: 10.1158/1541-7786.MCR-07-0197
Liu, D. et al. Autophagy regulates the survival of cells with chromosomal instability. Oncotarget 7, 63913–63923 (2016).
pubmed: 27590505
pmcid: 5325413
doi: 10.18632/oncotarget.11736
Wu, H., Wang, M. C. & Bohmann, D. JNK protects Drosophila from oxidative stress by trancriptionally activating autophagy. Mech. Dev. 126, 624–637 (2009).
pubmed: 19540338
pmcid: 2750887
doi: 10.1016/j.mod.2009.06.1082
Cohen-Sharir, Y. et al. Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. Nature 590, 486–491 (2021).
pubmed: 33505028
pmcid: 8262644
doi: 10.1038/s41586-020-03114-6
Payton, M. et al. Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers. Nat. Cancer 5, 66–84 (2023).
pubmed: 38151625
pmcid: 10824666
doi: 10.1038/s43018-023-00699-5
Quinton, R. J. et al. Whole-genome doubling confers unique genetic vulnerabilities on tumour cells. Nature 590, 492–497 (2021).
pubmed: 33505027
pmcid: 7889737
doi: 10.1038/s41586-020-03133-3
Zhang, R. et al. Discovery of potent, orally active KIF18A inhibitors targeting CIN-high cancer cells. J. Clin. Oncol. 40, e15046 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.e15046
Torres, E. M., Williams, B. R. & Amon, A. Aneuploidy: cells losing their balance. Genetics 179, 737–746 (2008).
pubmed: 18558649
pmcid: 2429870
doi: 10.1534/genetics.108.090878
Bielski, C. M. & Taylor, B. S. Homing in on genomic instability as a therapeutic target in cancer. Nat. Commun. 12, 3663 (2021).
pubmed: 34135330
pmcid: 8209011
doi: 10.1038/s41467-021-23965-5
Morden, C. R. et al. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples. Gynecol. Oncol. 161, 769–778 (2021).
pubmed: 33714608
doi: 10.1016/j.ygyno.2021.02.038
Colombo, N. et al. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol. Oncol. 163, 41–49 (2021).
pubmed: 34353615
pmcid: 9555119
doi: 10.1016/j.ygyno.2021.07.016
Gonzalez-Martin, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391–2402 (2019).
pubmed: 31562799
doi: 10.1056/NEJMoa1910962
Wethington, S. L. et al. Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer. Clin. Cancer Res. 29, 2800–2807 (2023).
pubmed: 37097611
doi: 10.1158/1078-0432.CCR-22-2444
Kulkarni, S. et al. Evolving DNA repair synthetic lethality targets in cancer. Biosci. Rep. 42, BSR20221713 (2022).
pubmed: 36420962
pmcid: 9760629
doi: 10.1042/BSR20221713
Weaver, B. A. How Taxol/paclitaxel kills cancer cells. Mol. Biol. Cell 25, 2677–2681 (2014).
pubmed: 25213191
pmcid: 4161504
doi: 10.1091/mbc.e14-04-0916
Marquis, C. et al. Chromosomally unstable tumor cells specifically require KIF18A for proliferation. Nat. Commun. 12, 1213 (2021).
pubmed: 33619254
pmcid: 7900194
doi: 10.1038/s41467-021-21447-2
Sousa-Pimenta, M. et al. Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel. Front. Pharmacol. 14, 1157306 (2023).
pubmed: 37229270
pmcid: 10203197
doi: 10.3389/fphar.2023.1157306
Komlodi-Pasztor, E., Sackett, D. L. & Fojo, A. T. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin. Cancer Res. 18, 51–63 (2012).
pubmed: 22215906
doi: 10.1158/1078-0432.CCR-11-0999
Van den Bossche, J. et al. Spotlight on volasertib: preclinical and clinical evaluation of a promising Plk1 inhibitor. Med. Res. Rev. 36, 749–786 (2016).
pubmed: 27140825
doi: 10.1002/med.21392
Benten, D. et al. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 11, 934–944 (2009).
pubmed: 19724687
pmcid: 2735802
doi: 10.1593/neo.09664
Serrano-Del Valle, A. et al. Future prospects for mitosis-targeted antitumor therapies. Biochem. Pharmacol. 190, 114655 (2021).
pubmed: 34129859
doi: 10.1016/j.bcp.2021.114655
Belmontes, B. et al. Abstract 516: dscovery and preclinical characterization of AMG 650, a first-in-class inhibitor of kinesin KIF18A motor protein with potent activity against chromosomally unstable cancers. Cancer Res. 83, 516 (2023).
doi: 10.1158/1538-7445.AM2023-516
Haykal, M. M., Rodrigues-Ferreira, S. & Nahmias, C. Aneuploidy triggers vulnerability to WEE1 inhibition via severe chromosome pulverization. Preprint at bioRxiv https://doi.org/10.1101/2023.09.19.558475 (2023).
doi: 10.1101/2023.09.19.558475
Lheureux, S. et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397, 281–292 (2021).
pubmed: 33485453
pmcid: 10792546
doi: 10.1016/S0140-6736(20)32554-X
Schutte, T. et al. Clinical development of WEE1 inhibitors in gynecological cancers: a systematic review. Cancer Treat. Rev. 115, 102531 (2023).
pubmed: 36893690
doi: 10.1016/j.ctrv.2023.102531
Liu, J. F. et al. Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC). J. Clin. Oncol. 41, https://doi.org/10.1200/JCO.2023.41.16_suppl.5513 (2023).
Gelderblom, H. et al. Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors — safety, pharmacokinetic, and preliminary antitumor activity data. J. Clin. Oncol. 41, https://doi.org/10.1200/JCO.2023.41.16_suppl.3012 (2023).
Guiley, K. Z. & Shokat, K. M. A small molecule reacts with the p53 somatic mutant Y220C to rescue wild-type thermal stability. Cancer Discov. 13, 56–69 (2023).
pubmed: 36197521
doi: 10.1158/2159-8290.CD-22-0381
Dumbrava, E. E. et al. First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation. J. Clin. Oncol. 40, 3003 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.3003
Murphy, T. et al. Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Leukemia 38, 502–512 (2024).
pubmed: 38114624
doi: 10.1038/s41375-023-02110-9
Meitinger, F. et al. TRIM37 controls cancer-specific vulnerability to PLK4 inhibition. Nature 585, 440–446 (2020).
pubmed: 32908304
pmcid: 7501188
doi: 10.1038/s41586-020-2710-1
Yeow, Z. Y. et al. Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer. Nature 585, 447–452 (2020).
pubmed: 32908313
pmcid: 7597367
doi: 10.1038/s41586-020-2690-1
Ippolito, M. R. et al. Increased RNA and protein degradation is required for counteracting transcriptional burden and proteotoxic stress in human aneuploid cells. Preprint at bioRxiv https://doi.org/10.1101/2023.01.27.525826 (2023).
doi: 10.1101/2023.01.27.525826
Zerbib, J. et al. Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage. Preprint at bioRxiv https://doi.org/10.1101/2023.01.27.525822 (2023).
doi: 10.1101/2023.01.27.525822
Flynn, P. J., Koch, P. D. & Mitchison, T. J. Chromatin bridges, not micronuclei, activate cGAS after drug-induced mitotic errors in human cells. Proc. Natl Acad. Sci. USA 118, e2103585118 (2021).
pubmed: 34819364
pmcid: 8640936
doi: 10.1073/pnas.2103585118
Bakhoum, S. F. Targeting the undruggable. Science 380, 47 (2023).
pubmed: 37023189
doi: 10.1126/science.adg7671
Tang, S., Stokasimov, E., Cui, Y. & Pellman, D. Breakage of cytoplasmic chromosomes by pathological DNA base excision repair. Nature 606, 930–936 (2022).
pubmed: 35477155
pmcid: 10680091
doi: 10.1038/s41586-022-04767-1
Hatch, E. M., Fischer, A. H., Deerinck, T. J. & Hetzer, M. W. Catastrophic nuclear envelope collapse in cancer cell micronuclei. Cell 154, 47–60 (2013).
pubmed: 23827674
pmcid: 3749778
doi: 10.1016/j.cell.2013.06.007
Dou, Z. et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature 550, 402–406 (2017).
pubmed: 28976970
pmcid: 5850938
doi: 10.1038/nature24050
Gluck, S. et al. Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. Nat. Cell. Biol. 19, 1061–1070 (2017).
pubmed: 28759028
pmcid: 5826565
doi: 10.1038/ncb3586
Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791 (2013).
pubmed: 23258413
doi: 10.1126/science.1232458
Wu, J. et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339, 826–830 (2013).
pubmed: 23258412
doi: 10.1126/science.1229963
Liu, S. et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science 347, aaa2630 (2015).
pubmed: 25636800
doi: 10.1126/science.aaa2630
Fitzgerald, K. A. et al. IKKε and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4, 491–496 (2003).
pubmed: 12692549
doi: 10.1038/ni921
Sharma, S. et al. Triggering the interferon antiviral response through an IKK-related pathway. Science 300, 1148–1151 (2003).
pubmed: 12702806
doi: 10.1126/science.1081315
Carozza, J. A. et al. Extracellular cGAMP is a cancer cell-produced immunotransmitter involved in radiation-induced anti-cancer immunity. Nat. Cancer 1, 184–196 (2020).
pubmed: 33768207
pmcid: 7990037
doi: 10.1038/s43018-020-0028-4
Li, X., Wang, F., Xu, X., Zhang, J. & Xu, G. The dual role of STAT1 in ovarian cancer: insight into molecular mechanisms and application potentials. Front. Cell Dev. Biol. 9, 636595 (2021).
pubmed: 33834023
pmcid: 8021797
doi: 10.3389/fcell.2021.636595
Dunn, G. P. et al. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 6, 722–729 (2005).
pubmed: 15951814
doi: 10.1038/ni1213
Jin, J. et al. Noncanonical NF-κB pathway controls the production of type I interferons in antiviral innate immunity. Immunity 40, 342–354 (2014).
pubmed: 24656046
pmcid: 3983709
doi: 10.1016/j.immuni.2014.02.006
Xu, Y. et al. SN52, a novel nuclear factor-κB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation. Mol. Cancer Ther. 7, 2367–2376 (2008).
pubmed: 18723484
pmcid: 2692185
doi: 10.1158/1535-7163.MCT-08-0238
Yamada, T. et al. Constitutive aryl hydrocarbon receptor signaling constrains type I interferon-mediated antiviral innate defense. Nat. Immunol. 17, 687–694 (2016).
pubmed: 27089381
doi: 10.1038/ni.3422
Toufektchan, E. et al. Intratumoral TREX1 induction promotes immune evasion by limiting type I interferon. Cancer Immunol. Res. 12, 673–686 (2024).
pubmed: 38408184
pmcid: 11148545
doi: 10.1158/2326-6066.CIR-23-1093
Yap, T. A. et al. 27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target. ESMO Open 8, 100993 (2023).
doi: 10.1016/j.esmoop.2023.100993
Gozgit, J. M. et al. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. Cancer Cell 39, 1214–1226.e10 (2021).
pubmed: 34375612
doi: 10.1016/j.ccell.2021.06.018
Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618 (2017).
pubmed: 28598415
pmcid: 5472757
doi: 10.1038/ncomms15618
Francica, B. et al. Abstract 2075: systemic small molecule TREX1 inhibitors to selectively activate STING in the TME of metastatic disease. Cancer Res. 82, 2075–2075 (2022).
doi: 10.1158/1538-7445.AM2022-2075
Tani, T. et al. TREX1 inactivation unleashes cancer cell STING-interferon signaling and promotes anti-tumor immunity. Cancer Discov. 14, 752–765 (2024).
pubmed: 38227896
doi: 10.1158/2159-8290.CD-23-0700
Zimmerli, D. et al. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. Nat. Commun. 13, 6579 (2022).
pubmed: 36323660
pmcid: 9630413
doi: 10.1038/s41467-022-34000-6
Muthalagu, N. et al. Repression of the type I interferon pathway underlies MYC- and KRAS-dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma. Cancer Discov. 10, 872–887 (2020).
pubmed: 32200350
pmcid: 7611248
doi: 10.1158/2159-8290.CD-19-0620
Li, Q. et al. Therapeutic development by targeting the cGAS-STING pathway in autoimmune disease and cancer. Front Pharm. 12, 779425 (2021).
doi: 10.3389/fphar.2021.779425
Wang, Y. et al. Aneuploidy landscape in precursors of ovarian cancer. Clin. Cancer Res. 30, 600–615 (2023).
doi: 10.1158/1078-0432.CCR-23-0932
Carozza, J. A. et al. ENPP1’s regulation of extracellular cGAMP is a ubiquitous mechanism of attenuating STING signaling. Proc. Natl Acad. Sci. USA 119, e2119189119 (2022).
pubmed: 35588451
pmcid: 9173814
doi: 10.1073/pnas.2119189119
Cogan, D. & Bakhoum, S. F. Re-awakening innate immune signaling in cancer: the development of highly potent ENPP1 inhibitors. Cell Chem. Biol. 27, 1327–1328 (2020).
pubmed: 33217310
pmcid: 8221070
doi: 10.1016/j.chembiol.2020.11.001
Solomon, P. E. et al. Discovery of VH domains that allosterically inhibit ENPP1. Nat. Chem. Biol. 20, 30–41 (2024).
pubmed: 37400538
doi: 10.1038/s41589-023-01368-5
Csiki, I. et al. 195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors. Immuno-Oncol. Technol. 16, 100307 (2022).
doi: 10.1016/j.iotech.2022.100307
Thompson, E. A. & Powell, J. D. Inhibition of the adenosine pathway to potentiate cancer immunotherapy: potential for combinatorial approaches. Annu. Rev. Med. 72, 331–348 (2021).
pubmed: 32903139
doi: 10.1146/annurev-med-060619-023155
Decout, A., Katz, J. D., Venkatraman, S. & Ablasser, A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 21, 548–569 (2021).
pubmed: 33833439
pmcid: 8029610
doi: 10.1038/s41577-021-00524-z
Li, J. & Bakhoum, S. F. The pleiotropic roles of cGAS-STING signaling in the tumor microenvironment. J. Mol. Cell. Biol. 14, mjac019 (2022).
pubmed: 35325182
pmcid: 9354322
doi: 10.1093/jmcb/mjac019
Hong, C. et al. cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers. Nature 607, 366–373 (2022).
pubmed: 35705809
doi: 10.1038/s41586-022-04847-2
Laks, E. et al. Clonal decomposition and DNA replication states defined by scaled single-cell genome sequencing. Cell 179, 1207–1221.e22 (2019).
pubmed: 31730858
pmcid: 6912164
doi: 10.1016/j.cell.2019.10.026
Funnell, T. et al. Single-cell genomic variation induced by mutational processes in cancer. Nature 612, 106–115 (2022).
pubmed: 36289342
pmcid: 9712114
doi: 10.1038/s41586-022-05249-0
Zhou, H. et al. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse. Breast Cancer Res. Treat. 178, 63–73 (2019).
pubmed: 31364001
doi: 10.1007/s10549-019-05375-w
Christodoulou, E. et al. Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors. NPJ Precis. Oncol. 7, 21 (2023).
pubmed: 36805676
pmcid: 9941464
doi: 10.1038/s41698-023-00357-0
Bethune, G. et al. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as ‘equivocal’ for HER2 gene amplification by fluorescence in-situ hybridization. Histopathology. 67, 880–887 (2015).
pubmed: 25913507
doi: 10.1111/his.12723
Akkari, Y. M. N. et al. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood 139, 2273–2284 (2022).
pubmed: 35167654
pmcid: 9710485
doi: 10.1182/blood.2021014309
Bakhoum, S. F., Danilova, O. V., Kaur, P., Levy, N. B. & Compton, D. A. Chromosomal instability substantiates poor prognosis in patients with diffuse large B-cell lymphoma. Clin. Cancer Res. 17, 7704–7711 (2011).
pubmed: 22184286
pmcid: 3244806
doi: 10.1158/1078-0432.CCR-11-2049
Xu, Z. et al. Deep learning predicts chromosomal instability from histopathology images. IScience 24, 102394 (2021).
pubmed: 33997679
pmcid: 8099498
doi: 10.1016/j.isci.2021.102394
Negoto, T. et al. Profiling chromosomal-level variations in gastric malignancies. Cancer Sci. 113, 3864–3876 (2022).
pubmed: 36002148
pmcid: 9633305
doi: 10.1111/cas.15544
Matsuura, T. et al. Histological diagnosis of polyploidy discriminates an aggressive subset of hepatocellular carcinomas with poor prognosis. Br. J. Cancer 129, 1251–1260 (2023).
pubmed: 37715023
pmcid: 10576083
doi: 10.1038/s41416-023-02408-6
Paniagua, I. & Jacobs, J. J. L. Quantification of chromosomal aberrations in mammalian cells. Bio-Protocol 13, e4739 (2023).
pubmed: 37638291
pmcid: 10450737
doi: 10.21769/BioProtoc.4739
Jones, G. D. et al. A genomic-pathologic annotated risk model to predict recurrence in early-stage lung adenocarcinoma. JAMA Surg. 156, e205601 (2021).
pubmed: 33355651
doi: 10.1001/jamasurg.2020.5601
Tsang, E. S. et al. Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration. NPJ Precis. Oncol. 7, 31 (2023).
pubmed: 36964191
pmcid: 10039042
doi: 10.1038/s41698-023-00368-x
Timms, K. M. et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 16, 475 (2014).
pubmed: 25475740
pmcid: 4308910
doi: 10.1186/s13058-014-0475-x
Vazquez-Garcia, I. et al. Ovarian cancer mutational processes drive site-specific immune evasion. Nature 612, 778–786 (2022).
pubmed: 36517593
pmcid: 9771812
doi: 10.1038/s41586-022-05496-1
Watkins, T. B. K. et al. Pervasive chromosomal instability and karyotype order in tumour evolution. Nature 587, 126–132 (2020).
pubmed: 32879494
pmcid: 7611706
doi: 10.1038/s41586-020-2698-6
Frezza, A. M. et al. CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: results from the ISG-STS 1001 study. Cancer Med. 12, 1350–1357 (2023).
pubmed: 35848358
doi: 10.1002/cam4.5015
Lynch, A. R., Arp, N. L., Zhou, A. S., Weaver, B. A. & Burkard, M. E. Quantifying chromosomal instability from intratumoral karyotype diversity using agent-based modeling and Bayesian inference. eLife 11, e69799 (2022).
pubmed: 35380536
pmcid: 9054132
doi: 10.7554/eLife.69799
Agustinus, A. S. et al. Epigenetic dysregulation from chromosomal transit in micronuclei. Nature 619, 176–183 (2023).
pubmed: 37286593
pmcid: 10322720
doi: 10.1038/s41586-023-06084-7
Coy, S. et al. 2D and 3D multiplexed subcellular profiling of nuclear instability in human cancer. Preprint at bioRxiv https://doi.org/10.1101/2023.11.07.566063 (2023).
doi: 10.1101/2023.11.07.566063
pubmed: 37986801
pmcid: 10659270
Schonhoft, J. D. et al. Morphology-predicted large-scale transition number in circulating tumor cells identifies a chromosomal instability biomarker associated with poor outcome in castration-resistant prostate cancer. Cancer Res. 80, 4892–4903 (2020).
pubmed: 32816908
pmcid: 8428781
doi: 10.1158/0008-5472.CAN-20-1216
Freitas, M. O., Gartner, J., Rangel-Pozzo, A. & Mai, S. Genomic instability in circulating tumor cells. Cancers 12, 3001 (2020).
pubmed: 33081135
pmcid: 7602879
doi: 10.3390/cancers12103001
Chen, Z. et al. Chromosomal instability of circulating tumor DNA reflect therapeutic responses in advanced gastric cancer. Cell Death Dis. 10, 697 (2019).
pubmed: 31541076
pmcid: 6754425
doi: 10.1038/s41419-019-1907-4
Tamayo, N. A. et al. Targeting the mitotic kinesin KIF18A in chromosomally unstable cancers: hit optimization toward an in vivo chemical probe. J. Med. Chem. 65, 4972–4990 (2022).
pubmed: 35286090
doi: 10.1021/acs.jmedchem.1c02030
Di Bona, M. & Bakhoum, S. F. Micronuclei and cancer. Cancer Discov. 14, 214–226 (2024).
pubmed: 38197599
doi: 10.1158/2159-8290.CD-23-1073
Crasta, K. et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature 482, 53–58 (2012).
pubmed: 22258507
pmcid: 3271137
doi: 10.1038/nature10802
Liu, S. et al. Nuclear envelope assembly defects link mitotic errors to chromothripsis. Nature 561, 551–555 (2018).
pubmed: 30232450
pmcid: 6599625
doi: 10.1038/s41586-018-0534-z
Maciejowski, J., Li, Y., Bosco, N., Campbell, P. J. & de Lange, T. Chromothripsis and kataegis induced by telomere crisis. Cell 163, 1641–1654 (2015).
pubmed: 26687355
pmcid: 4687025
doi: 10.1016/j.cell.2015.11.054
Ly, P. et al. Chromosome segregation errors generate a diverse spectrum of simple and complex genomic rearrangements. Nat. Genet. 51, 705–715 (2019).
pubmed: 30833795
pmcid: 6441390
doi: 10.1038/s41588-019-0360-8
Shoshani, O. et al. Chromothripsis drives the evolution of gene amplification in cancer. Nature 591, 137–141 (2021).
pubmed: 33361815
doi: 10.1038/s41586-020-03064-z
Umbreit, N. T. et al. Mechanisms generating cancer genome complexity from a single cell division error. Science 368, eaba0712 (2020).
pubmed: 32299917
pmcid: 7347108
doi: 10.1126/science.aba0712